AUT 00206

Drug Profile

AUT 00206

Alternative Names: AUT00206

Latest Information Update: 08 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Autifony Therapeutics; University of Manchester; University of Newcastle upon Tyne
  • Class Antipsychotics; Small molecules
  • Mechanism of Action Shaw potassium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Schizophrenia
  • Preclinical Fragile X syndrome

Most Recent Events

  • 01 Nov 2017 Autifony Therapeutics completes a phase Ib trial in Healthy volunteers in United Kingdom (PO) (NCT02935725)
  • 10 Jul 2017 Preclinical trials in Fragile X syndrome in United Kingdom (PO)
  • 10 Jul 2017 AUT 00206 receives Orphan Drug status for Fragile X syndrome in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top